Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines

Ali Azizi; Gathoni Kamuyu; Deborah Ogbeni; Philipa Levesque-Damphousse; Daniel Knott; Luc Gagnon; Steven Phay-Tran; Bethan Hussey; Pamela Proud; Sue Charlton; Carolyn Clark; Valentina Bernasconi

doi:10.1080/21645515.2024.2344249

Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines

Ali Azizi^*, Gathoni Kamuyu, Deborah Ogbeni, Philipa Levesque-Damphousse, Daniel Knott, Luc Gagnon, Steven Phay-Tran, Bethan Hussey, Pamela Proud, Sue Charlton, Carolyn Clark, Valentina Bernasconi

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

2 Citations (Scopus)

Abstract

To date, thousands of SARS-CoV-2 samples from many vaccine developers have been tested within the CEPI-Centralized Laboratory Network. To convert data from each clinical assay to international standard units, the WHO international standard and the CEPI standard generated by the Medicines and Healthcare products Regulatory Agency were run in multiple facilities to determine the conversion factor for each assay. Reporting results in international units advances global understanding of SARS-CoV-2 immunity and vaccine efficacy, enhancing the quality, reliability, and utility of clinical assay data.

Original language	English
Article number	2344249
Journal	Human Vaccines and Immunotherapeutics
Volume	20
Issue number	1
DOIs	https://doi.org/10.1080/21645515.2024.2344249
Publication status	Published - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

Keywords

CEPI-CLN
SARS-CoV-2 pandemic
immunological assays
standardization
vaccine efficacy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/21645515.2024.2344249

Cite this

Azizi, A., Kamuyu, G., Ogbeni, D., Levesque-Damphousse, P., Knott, D., Gagnon, L., Phay-Tran, S., Hussey, B., Proud, P., Charlton, S., Clark, C., & Bernasconi, V. (2024). Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines. Human Vaccines and Immunotherapeutics, 20(1), Article 2344249. https://doi.org/10.1080/21645515.2024.2344249

@article{8f62ffdbf51e498c8b0e9150a9737294,

title = "Driving consistency: CEPI-Centralized Laboratory Network{\textquoteright}s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines",

abstract = "To date, thousands of SARS-CoV-2 samples from many vaccine developers have been tested within the CEPI-Centralized Laboratory Network. To convert data from each clinical assay to international standard units, the WHO international standard and the CEPI standard generated by the Medicines and Healthcare products Regulatory Agency were run in multiple facilities to determine the conversion factor for each assay. Reporting results in international units advances global understanding of SARS-CoV-2 immunity and vaccine efficacy, enhancing the quality, reliability, and utility of clinical assay data.",

keywords = "CEPI-CLN, SARS-CoV-2 pandemic, immunological assays, standardization, vaccine efficacy",

author = "Ali Azizi and Gathoni Kamuyu and Deborah Ogbeni and Philipa Levesque-Damphousse and Daniel Knott and Luc Gagnon and Steven Phay-Tran and Bethan Hussey and Pamela Proud and Sue Charlton and Carolyn Clark and Valentina Bernasconi",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

doi = "10.1080/21645515.2024.2344249",

language = "English",

volume = "20",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Landes Bioscience",

number = "1",

}

Azizi, A, Kamuyu, G, Ogbeni, D, Levesque-Damphousse, P, Knott, D, Gagnon, L, Phay-Tran, S, Hussey, B, Proud, P , Charlton, S, Clark, C & Bernasconi, V 2024, 'Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines', Human Vaccines and Immunotherapeutics, vol. 20, no. 1, 2344249. https://doi.org/10.1080/21645515.2024.2344249

TY - JOUR

T1 - Driving consistency

T2 - CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines

AU - Azizi, Ali

AU - Kamuyu, Gathoni

AU - Ogbeni, Deborah

AU - Levesque-Damphousse, Philipa

AU - Knott, Daniel

AU - Gagnon, Luc

AU - Phay-Tran, Steven

AU - Hussey, Bethan

AU - Proud, Pamela

AU - Charlton, Sue

AU - Clark, Carolyn

AU - Bernasconi, Valentina

PY - 2024

Y1 - 2024

N2 - To date, thousands of SARS-CoV-2 samples from many vaccine developers have been tested within the CEPI-Centralized Laboratory Network. To convert data from each clinical assay to international standard units, the WHO international standard and the CEPI standard generated by the Medicines and Healthcare products Regulatory Agency were run in multiple facilities to determine the conversion factor for each assay. Reporting results in international units advances global understanding of SARS-CoV-2 immunity and vaccine efficacy, enhancing the quality, reliability, and utility of clinical assay data.

AB - To date, thousands of SARS-CoV-2 samples from many vaccine developers have been tested within the CEPI-Centralized Laboratory Network. To convert data from each clinical assay to international standard units, the WHO international standard and the CEPI standard generated by the Medicines and Healthcare products Regulatory Agency were run in multiple facilities to determine the conversion factor for each assay. Reporting results in international units advances global understanding of SARS-CoV-2 immunity and vaccine efficacy, enhancing the quality, reliability, and utility of clinical assay data.

KW - CEPI-CLN

KW - SARS-CoV-2 pandemic

KW - immunological assays

KW - standardization

KW - vaccine efficacy

UR - http://www.scopus.com/inward/record.url?scp=85192181107&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/6f3ae750-67de-368a-bdf1-bb99499e68b8/

U2 - 10.1080/21645515.2024.2344249

DO - 10.1080/21645515.2024.2344249

M3 - Comment/debate

AN - SCOPUS:85192181107

SN - 2164-5515

VL - 20

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 1

M1 - 2344249

ER -

Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this